Actively Recruiting

Phase Not Applicable
Age: 18Years - 50Years
All Genders
Healthy Volunteers
ID03859050

Alveolar Macrophage Programming Following Endotoxin Exposure

Led by National Jewish Health · Updated on 2025-05-06

25

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research investigates the role and behavior of different types of alveolar macrophages in lung inflammation and repair, particularly after exposure to endotoxin. The study focuses on understanding how resident alveolar macrophages and recruited macrophages function independently yet work together during lung injury and healing. Researchers aim to better comprehend the cellular processes involved in conditions such as acute respiratory distress syndrome (ARDS). The study involves administering lipopolysaccharide (LPS), a substance that triggers inflammation, directly into the lungs of healthy adult volunteers through bronchoscopy. Participants then undergo bronchoalveolar lavage (BAL) at various time points—24, 48, 72, 96, or 120 hours after LPS exposure—to collect macrophages for analysis. This allows researchers to distinguish and count the different macrophage populations using advanced flow cytometry techniques. Participants will be closely monitored throughout the study period, which includes multiple bronchoscopy procedures and lung fluid collection. Researchers will assess the proportions of resident versus recruited macrophages seven days after LPS administration. Volunteers will undergo medical evaluations including spirometry and electrocardiograms to ensure safety. The study includes healthy adults aged 18 to 50, with continuous monitoring to understand immune responses following controlled lung inflammation.

CONDITIONS

Brief Title

Alveolar Macrophage Programming Following Endotoxin Exposure

Who Can Participate

Age: 18Years - 50Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Written, informed consent
  • Age 18 to 50 years
Not Eligible

You will not qualify if you...

  • Current or recent illness within the past 2 weeks
  • History of cardiac, pulmonary, or systemic disease
  • Bleeding disorder or use of blood thinners
  • American Society of Anesthesiology (ASA) class 2 or greater
  • Immunocompromised state including HIV or immunosuppressant use
  • Use of inhaled substances or smoking history over 10 pack-years
  • Alcohol use disorder or excessive drinking in the past 3 months
  • Allergy or prior adverse reaction to lidocaine, midazolam, or fentanyl
  • Abnormal lung function or heart tests at screening
  • Pregnant or breastfeeding women based on urine test

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Intervention

Duration - 5 days

Participants will undergo bronchoscopy with intrabronchial administration of lipopolysaccharide followed by bronchoalveolar lavage (BAL) to obtain macrophages at multiple time points.

1 bronchoscopy visit and up to 5 BAL visits over 5 days

Trial Site Locations

Total: 1 location

1

National Jewish Health

Denver, Colorado, United States, 80206

Actively Recruiting

Loading map...

Research Team

K

Kara Mould

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Similar Trials

Digital Intelligence Early Warning System for Acute Lung Inj...

Acute Lung Injury(ALI)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here